Cassava Sciences, Inc. at the International Conference on Clinical Trials on Alzheimer’s Disease (CTAD)

Dec 5, 2019
6:00 PM PST

Title: One-Month Oral Treatment With PTI-125, A New Drug Candidate, Reduces CSF and Plasma Biomarkers of Alzheimer’s Disease
Presentation Type: Late-Breaking Oral Presentation (LB6)
Presenter: Lindsay H. Burns, PhD, co-discoverer of PTI-125

Cassava Sciences’ CTAD presentation will be available on this website on the day of the presentation.

Location

Hilton Bayfront, San Diego